ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitisZORYVE, a next-generation topical phosphodiesterase-4 ...

Mizuho Securities analyst Uy Ear has maintained their bullish stance on ARQT stock, giving a Buy rating on November 11.Don't Miss our Black ...

Eczema is relatively common, affecting 20 percent of children and 10 percent of adults around the world (1). If you are one of the many who experiences eczema, you know the symptoms, which can include ...

Dermatologists have warned that applying adult skincare products and alcohol-based creams on babies puts them at risk of skin ...

Discover why analysts are bullish on Arcutis Biotherapeutics after strong Q3 results, despite recent market fluctuations in ...

Organon is a strong investment opportunity with a high yield, diversified portfolio, steady performance, and transformative ...

Therapy for atopic dermatitis is multi-faceted and encompasses ... Topical steroids are available in a wide variety of vehicles including creams, lotions, ointments, solutions, gels, and foams.

less well known is the fact that she lives with eczema and uses Opzelura cream to treat it. Featured alongside Moore in the ...

Many investors continue to be worried about Incyte’s financial prospects when the patent for the company’s blood cancer ...

Approval in atopic dermatitis could unlock additional sales momentum for Zoryve, which is available in a 0.3% cream for psoriasis and a 0.3% topical foam for seborrheic dermatitis. Those ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

An Auckland-based artist living with debilitating symptoms of topical steroid withdrawal (TSW) believes his dermatologists ...